Nivolumab + ipilimumab (N + I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy Meeting Abstract
| Authors: | Albiges, L.; Tannir, N.; Burotto, M.; McDermott, D. F.; Plimack, E. R.; Barthélémy, P.; Porta, C. G.; Powles, T. B.; Donskov, F.; George, S.; Kollmannsberger, C.; Gurney, H.; Grimm, M. O.; Tomita, Y.; Castellano Gauna, D.; Rini, B. I.; Choueiri, T. K.; Saggi, S. S.; McHenry, M. B.; Motzer, R. J. |
| Abstract Title: | Nivolumab + ipilimumab (N + I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy |
| Meeting Title: | ESMO Virtual Congress 2020 |
| Journal Title: | Annals of Oncology |
| Volume: | 31 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2020 Sep 19-21/Oct 16-18 |
| Meeting Location: | Virtual |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2020-09-01 |
| Start Page: | S559 |
| End Page: | S560 |
| Language: | English |
| ACCESSION: | WOS:000573469100707 |
| DOI: | 10.1016/j.annonc.2020.08.783 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 711P -- Source: Wos |
